Quarterly report pursuant to Section 13 or 15(d)

Schedule of Segments (Tables)

v3.8.0.1
Schedule of Segments (Tables)
3 Months Ended
Mar. 31, 2017
Schedule of Segments (Tables)  
Schedule of Segment Reporting Information, by Segment

The Company also has certain small cancer related legacy investments and an investment in note receivable from a non-affiliated party that is included in the Corporate and Eliminations section below.

 

 

Cannabis and Medical Marijuana Segment

Legacy Investment

Corporate and Eliminations

Consolidated

Three months ended March 2017

 

Net sales

$

-

$

738,144

$

-

$

738,144

Income before taxes

 

(299)

23,592

(464,509)

(441,216)

Interest income

 

-

1

28,293

28,294

Interest expense

 

-

5,184

(1,134)

4,050

Total assets

 

1,148,992

1,116,210

5,511,704

7,776,906

Property additions

 

-

-

-

-

Depreciation and amortization

 

-

3,323

625

3,948

 

Three months ended March 2016

 

Net sales

 

450

642,844

-

643,294

Income before taxes

 

4,094

20,745

(213,983)

(189,144)

Interest income

 

2,694

-

24,553

27,247

Interest expense

 

-

4,316

7,552

11,868

Total assets

 

1,607,772

1,123,451

1,575,690

4,306,913

Property additions

 

-

5,268

1,029

6,297

Depreciation and amortization

 

1,568

30,004

(25,634)

5,938